These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 17595114)

  • 1. Raman crystallographic studies of the intermediates formed by Ser130Gly SHV, a beta-lactamase that confers resistance to clinical inhibitors.
    Helfand MS; Taracila MA; Totir MA; Bonomo RA; Buynak JD; van den Akker F; Carey PR
    Biochemistry; 2007 Jul; 46(29):8689-99. PubMed ID: 17595114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High resolution crystal structures of the trans-enamine intermediates formed by sulbactam and clavulanic acid and E166A SHV-1 {beta}-lactamase.
    Padayatti PS; Helfand MS; Totir MA; Carey MP; Carey PR; Bonomo RA; van den Akker F
    J Biol Chem; 2005 Oct; 280(41):34900-7. PubMed ID: 16055923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different intermediate populations formed by tazobactam, sulbactam, and clavulanate reacting with SHV-1 beta-lactamases: Raman crystallographic evidence.
    Kalp M; Totir MA; Buynak JD; Carey PR
    J Am Chem Soc; 2009 Feb; 131(6):2338-47. PubMed ID: 19161282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the inhibitor-resistant M69V substitution on the structures and populations of trans-enamine beta-lactamase intermediates.
    Totir MA; Padayatti PS; Helfand MS; Carey MP; Bonomo RA; Carey PR; van den Akker F
    Biochemistry; 2006 Oct; 45(39):11895-904. PubMed ID: 17002290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitor-resistant class A beta-lactamases: consequences of the Ser130-to-Gly mutation seen in Apo and tazobactam structures of the SHV-1 variant.
    Sun T; Bethel CR; Bonomo RA; Knox JR
    Biochemistry; 2004 Nov; 43(44):14111-7. PubMed ID: 15518561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clavulanic acid inactivation of SHV-1 and the inhibitor-resistant S130G SHV-1 beta-lactamase. Insights into the mechanism of inhibition.
    Sulton D; Pagan-Rodriguez D; Zhou X; Liu Y; Hujer AM; Bethel CR; Helfand MS; Thomson JM; Anderson VE; Buynak JD; Ng LM; Bonomo RA
    J Biol Chem; 2005 Oct; 280(42):35528-36. PubMed ID: 15987690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Following the reactions of mechanism-based inhibitors with beta-lactamase by Raman crystallography.
    Helfand MS; Totir MA; Carey MP; Hujer AM; Bonomo RA; Carey PR
    Biochemistry; 2003 Nov; 42(46):13386-92. PubMed ID: 14621983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding resistance to beta-lactams and beta-lactamase inhibitors in the SHV beta-lactamase: lessons from the mutagenesis of SER-130.
    Helfand MS; Bethel CR; Hujer AM; Hujer KM; Anderson VE; Bonomo RA
    J Biol Chem; 2003 Dec; 278(52):52724-9. PubMed ID: 14534312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational design of a beta-lactamase inhibitor achieved via stabilization of the trans-enamine intermediate: 1.28 A crystal structure of wt SHV-1 complex with a penam sulfone.
    Padayatti PS; Sheri A; Totir MA; Helfand MS; Carey MP; Anderson VE; Carey PR; Bethel CR; Bonomo RA; Buynak JD; van den Akker F
    J Am Chem Soc; 2006 Oct; 128(40):13235-42. PubMed ID: 17017804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tazobactam forms a stoichiometric trans-enamine intermediate in the E166A variant of SHV-1 beta-lactamase: 1.63 A crystal structure.
    Padayatti PS; Helfand MS; Totir MA; Carey MP; Hujer AM; Carey PR; Bonomo RA; van den Akker F
    Biochemistry; 2004 Feb; 43(4):843-8. PubMed ID: 14744126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulbactam forms only minimal amounts of irreversible acrylate-enzyme with SHV-1 beta-lactamase.
    Totir MA; Helfand MS; Carey MP; Sheri A; Buynak JD; Bonomo RA; Carey PR
    Biochemistry; 2007 Aug; 46(31):8980-7. PubMed ID: 17630699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Penam sulfones and β-lactamase inhibition: SA2-13 and the importance of the C2 side chain length and composition.
    Rodkey EA; Winkler ML; Bethel CR; Pagadala SR; Buynak JD; Bonomo RA; van den Akker F
    PLoS One; 2014; 9(1):e85892. PubMed ID: 24454944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insight into the effect of inhibitor resistant S130G mutant on physico-chemical properties of SHV type beta-lactamase: a molecular dynamics study.
    Baig MH; Sudhakar DR; Kalaiarasan P; Subbarao N; Wadhawa G; Lohani M; Khan MK; Khan AU
    PLoS One; 2014; 9(12):e112456. PubMed ID: 25479359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam.
    Papp-Wallace KM; Winkler ML; Taracila MA; Bonomo RA
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3710-7. PubMed ID: 25666153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural consequences of the inhibitor-resistant Ser130Gly substitution in TEM beta-lactamase.
    Thomas VL; Golemi-Kotra D; Kim C; Vakulenko SB; Mobashery S; Shoichet BK
    Biochemistry; 2005 Jul; 44(26):9330-8. PubMed ID: 15981999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Avibactam and inhibitor-resistant SHV β-lactamases.
    Winkler ML; Papp-Wallace KM; Taracila MA; Bonomo RA
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3700-9. PubMed ID: 25691639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspartic acid for asparagine substitution at position 276 reduces susceptibility to mechanism-based inhibitors in SHV-1 and SHV-5 beta-lactamases.
    Giakkoupi P; Tzelepi E; Legakis NJ; Tzouvelekis LS
    J Antimicrob Chemother; 1999 Jan; 43(1):23-9. PubMed ID: 10381097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the SHV-1 beta-lactamase by sulfones: crystallographic observation of two reaction intermediates with tazobactam.
    Kuzin AP; Nukaga M; Nukaga Y; Hujer A; Bonomo RA; Knox JR
    Biochemistry; 2001 Feb; 40(6):1861-6. PubMed ID: 11327849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why the extended-spectrum beta-lactamases SHV-2 and SHV-5 are "hypersusceptible" to mechanism-based inhibitors.
    Kalp M; Bethel CR; Bonomo RA; Carey PR
    Biochemistry; 2009 Oct; 48(41):9912-20. PubMed ID: 19736945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming resistance to beta-lactamase inhibitors: comparing sulbactam to novel inhibitors against clavulanate resistant SHV enzymes with substitutions at Ambler position 244.
    Thomson JM; Distler AM; Bonomo RA
    Biochemistry; 2007 Oct; 46(40):11361-8. PubMed ID: 17848099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.